These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 26319226)
1. Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism. Kust D; Kruljac I; Peternac AŠ; Ostojić J; Prpić M; Čaržavec D; Gaćina P Acta Clin Belg; 2016 Jun; 71(3):175-7. PubMed ID: 26319226 [TBL] [Abstract][Full Text] [Related]
2. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350 [TBL] [Abstract][Full Text] [Related]
3. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature]. Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880 [TBL] [Abstract][Full Text] [Related]
4. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? Sella A; Hercbergs AH; Hanovich E; Kovel S Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787 [TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events? Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040 [TBL] [Abstract][Full Text] [Related]
6. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue]. Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151 [TBL] [Abstract][Full Text] [Related]
7. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma. Pilanc KN; Elbüken F; Ordu Ç; Köksal G; Tekelioğlu MH; Okutur K; Göksel S; Köksal Ü; Akçal T; Tecimer C Am J Ther; 2016; 23(2):e583-7. PubMed ID: 24901901 [TBL] [Abstract][Full Text] [Related]
8. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181 [TBL] [Abstract][Full Text] [Related]
9. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482 [TBL] [Abstract][Full Text] [Related]
10. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116 [TBL] [Abstract][Full Text] [Related]
11. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Grossmann M; Premaratne E; Desai J; Davis ID Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019 [TBL] [Abstract][Full Text] [Related]